COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED OR METASTATIC RENAL CELL CARCINOMA IN THE NETHERLANDS

被引：0
|
作者：
Klijn, S. [1 ]
Van de Wetering, G. [1 ]
Malcolm, B. [2 ]
Dale, P. [2 ]
Pompen, M. [3 ]
Stevanovic, J. [3 ]
机构：
[1] Pharmerit Int, Rotterdam, Netherlands
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Utrecht, Netherlands
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.09.272
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN190
引用
收藏
页码：S46 / S46
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
    Wu, Bin
    Zhang, Qiang
    Sun, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [2] COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE FIRST-LINE TREATMENT OF ADVANCED/METASTATIC RENAL CELL CARCINOMA IN GREECE
    Diamantogiannis, F.
    Viktoratos, P.
    May, J.
    Malcolm, B.
    Van de Wetering, G.
    Ignacio, T.
    VALUE IN HEALTH, 2019, 22 : S468 - S469
  • [3] First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma A Cost-effectiveness Analysis
    Wan, XiaoMin
    Zhang, YuCong
    Tan, ChongQing
    Zeng, XiaoHui
    Peng, LiuBao
    JAMA ONCOLOGY, 2019, 5 (04) : 491 - 496
  • [4] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Cakar, Esra
    Oniangue-Ndza, Cesar
    Schneider, Ralph P. P.
    Klijn, Sven L. L.
    Vogl, Ursula M. M.
    Rothermundt, Christian
    May, Jessica R. R.
    PHARMACOECONOMICS-OPEN, 2023, 7 (04) : 567 - 577
  • [5] Cost-Effectiveness of Nivolumab Plus Ipilimumab for the First-Line Treatment of Intermediate/Poor-Risk Advanced and/or Metastatic Renal Cell Carcinoma in Switzerland
    Esra Çakar
    César Oniangue-Ndza
    Ralph P. Schneider
    Sven L. Klijn
    Ursula M. Vogl
    Christian Rothermundt
    Jessica R. May
    PharmacoEconomics - Open, 2023, 7 : 567 - 577
  • [6] Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
    Watson, Tina R.
    Gao, Xin
    Reynolds, Kerry L.
    Kong, Chung Yin
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [7] Cost-effectiveness Analysis of Nivolumab Plus Ipilimumab Combination Therapy as First-line Treatment for Advanced Renal Cell Carcinoma in Japan
    Maeda, Tomomi
    Moriwaki, Kensuke
    Morimoto, Kosuke
    Yoshioka, Takashi
    Goto, Rei
    Shimozuma, Kojiro
    VALUE IN HEALTH REGIONAL ISSUES, 2024, 40 : 118 - 126
  • [8] Cost-effectiveness of Nivolumab Plus Cabozantinib Versus Cabozantinib as First-Line Treatment of Metastatic Renal Cell Carcinoma
    Liu, Tong
    Jin, Yao
    Dong, Mei
    CLINICAL GENITOURINARY CANCER, 2023, 21 (06) : E449 - E460
  • [9] COST-EFFECTIVENESS OF NIVOLUMAB plus IPILIMUMAB IN FIRST -LINE TREATMENT OF ADVANCED MELANOMA
    Baker, T. M.
    Paly, V. F.
    Sabater, J.
    Okoro, T.
    Kotapati, S.
    Briggs, A.
    VALUE IN HEALTH, 2016, 19 (07) : A730 - A730
  • [10] COST-EFFECTIVENESS OF PEMBROLIZUMAB plus AXITINIB VERSUS NIVOLUMAB plus IPILIMUMAB AS FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL
    Garmatter, L. P. Leonart
    Berlinski, F.
    Rego, M. A. D. C.
    Bastos, D. A.
    Soares, A.
    Kater, F. R.
    Nunes, A. A.
    Santos, M.
    Riveros, B. Salgado
    VALUE IN HEALTH, 2023, 26 (06) : S149 - S150
12345